|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2300068744 |
|
最近更新日期: Date of Last Refreshed on: |
2023-02-28 15:09:53 |
|
注册时间: Date of Registration: |
2023-02-28 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
丘脑底核-黑质网状部双靶点联合电刺激治疗帕金森病冻结步态随机交叉对照研究 |
|
Public title: |
Subthalamic nucleus and substantia nigra pars reticulata combined stimulation for freezing of gait in Parkinson's disease. A randomized double-blinded cross-over study |
|
注册题目简写: |
STN-SNr combined stimulation for FoG in PD |
|
English Acronym: |
|
|
研究课题的正式科学名称: |
丘脑底核-黑质网状部双靶点联合电刺激治疗帕金森病冻结步态随机交叉对照研究 |
|
Scientific title: |
Subthalamic nucleus and substantia nigra pars reticulata combined stimulation for freezing of gait in Parkinson's disease. A randomized double-blinded cross-over study |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
任志伟 |
研究负责人: |
李建宇 |
|
Applicant: |
Zhiwei Ren |
Study leader: |
Jianyu Li |
|
申请注册联系人电话: Applicant telephone: |
+86 010-83198882 |
研究负责人电话: Study leader's telephone: |
+86 010-83199238 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
geekai@163.com |
研究负责人电子邮件: Study leader's E-mail: |
lijianyu@vip.sohu.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
北京市西城区长椿街45号 |
研究负责人通讯地址: |
北京市西城区长椿街45号 |
|
Applicant address: |
45 Changchun Street, Xicheng District, Beijing |
Study leader's address: |
45 Changchun Street, Xicheng District, Beijing |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
首都医科大学宣武医院 |
||
|
Applicant's institution: |
Xuanwu Hospital, Capital Medical University |
||
|
研究负责人所在单位: |
首都医科大学宣武医院 |
||
|
Affiliation of the Leader: |
Xuanwu Hospital, Capital Medical University |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
临研审[2022]176号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
首都医科大学宣武医院伦理委员会 |
||
|
Name of the ethic committee: |
IRB of Xuanwu Hospital, Capital Medical University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2022-11-18 00:00:00 |
||
|
伦理委员会联系人: |
沈芊 |
||
|
Contact Name of the ethic committee: |
Qian Shen |
||
|
伦理委员会联系地址: |
北京市西城区长椿街45号 |
||
|
Contact Address of the ethic committee: |
45 Changchun Street, Xicheng District, Beijing |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 10 83199270 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
首都医科大学宣武医院 |
||||||||||||||||||||||||||||||||||||||||||||
|
Primary sponsor: |
Xuanwu Hospital, Capital Medical University |
||||||||||||||||||||||||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
北京市西城区长椿街45号 |
||||||||||||||||||||||||||||||||||||||||||||
|
Primary sponsor's address: |
45 Changchun Street, Xicheng District, Beijing |
||||||||||||||||||||||||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||||||||||||||||||||||||
|
经费或物资来源: |
首都医科大学宣武医院 |
||||||||||||||||||||||||||||||||||||||||||||
|
Source(s) of funding: |
Xuanwu Hospital,Capital Medical University |
||||||||||||||||||||||||||||||||||||||||||||
|
Target disease: |
Parkinson's disease |
||||||||||||||||||||||||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||||||||||||||||||||||||
|
研究所处阶段: |
治疗新技术临床试验 | ||||||||||||||||||||||||||||||||||||||||||||
|
Study phase: |
New Treatment Measure Clinical Study |
||||||||||||||||||||||||||||||||||||||||||||
|
研究设计: |
随机交叉对照 |
||||||||||||||||||||||||||||||||||||||||||||
|
Study design: |
Cross-over |
||||||||||||||||||||||||||||||||||||||||||||
|
研究目的: |
采用随机交叉分组方法,评估传统单独STN脑深部电刺激与STN-SNr联合电刺激对帕金森病患者冻结步态症状改善的差异,提高对帕金森病步态症状治疗效果,制定一套新的手术靶点计划及术后程控标准。 |
||||||||||||||||||||||||||||||||||||||||||||
|
Objectives of Study: |
Use randomized cross-over study, to evaluate the differences of traditional STN stimulation and STN-SNr combined stimulation for freezing of gait of Parkinson's disease, improve the treatment effect of gait disorders of Parkinson's disease, and establish a new set of DBS targeting method and postoperative programming protocol. |
||||||||||||||||||||||||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||||||||||||||||||||||||
|
纳入标准: |
1.诊断为原发性帕金森病,病程≥5年;2.于首都医科大学帕金森病临床诊疗于研究中心评估及随访,拟行以丘脑底核(STN)为手术靶点的立体定向手术患者;3.多巴胺能药物治疗仍有难以控制的步态障碍(最优化的临床条件下的综合“轴向评分”≥ 12,UPDRS II的第13-15项及UPDRS III的第27-31项为“轴性症状评分”);4.能够配合完成磁共振T1、T2、QSM序列扫描者;5.无神经外科手术禁忌,签署知情同意书者;6.术后1年内能够完成随访者。 |
||||||||||||||||||||||||||||||||||||||||||||
|
Inclusion criteria |
1. Those who meet the diagnostic criteria of primary Parkinson's disease at least 5 years; 2. Patients who take evaluation and follow-up at Clinical Center for Parkinson's Disease, Capital Medical University, plan to undergo subthalamic nucleus (STN) DBS surgery; 3. Those who can cooperate to complete T1w, T2w and QSM MR scanning; 4. There is no contraindication of neurosurgery and the informed consent is signed; 5. Those who can complete follow-up within 1 year after surgery. |
||||||||||||||||||||||||||||||||||||||||||||
|
排除标准: |
1.有金属植入物或因生理心理等原因不能配合完成长时间磁共振扫描者;2.有手术禁忌症者;3.在过去三个月内和在研究登记期间参与其他临床试验;4.患有其他可能混淆治疗效果或数据解释的严重慢性疾病。 |
||||||||||||||||||||||||||||||||||||||||||||
|
Exclusion criteria: |
1. Those who have metal implants or cannot complete long-term MRI scanning due to physiological and psychological reasons; 2. Contraindications to surgery; 3. Participate in other clinical trials in the past 3 months during the study registration period; 4. Suffered from other serious chronic diseases that may confuse the treatment effect or data interpretation. |
||||||||||||||||||||||||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2023-03-01 00:00:00至 To 2024-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2023-03-01 00:00:00 至 To 2024-10-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
正在进行 Recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
宣武医院循证医学中心电话分配随机序列 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Telephone assign Random Sequence by Evidence-based Medicine Center of Xuanwu Hospital |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
|
|
Blinding: |
|
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
随访结束1年公开数据 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
1 year after follow-up |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
数据采集用病例记录表完成,原始数据由宣武医院循证医学中心统一管理 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Data collection completed with case record form |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |